⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYTX News
Kyverna Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
globenewswire.com
KYTX
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
globenewswire.com
KYTX